Zentalis Pharmaceuticals (ZNTL)
(Real Time Quote from BATS)
$3.97 USD
-0.01 (-0.25%)
Updated Jul 12, 2024 11:32 AM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
ZNTL 3.97 -0.01(-0.25%)
Will ZNTL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ZNTL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZNTL
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
ZNTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
Other News for ZNTL
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome: AL102 And Other Established Protein Targets Could Drive Value
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX), Zentalis Pharmaceuticals (ZNTL) and PTC Therapeutics (PTCT)
Wall Street Breakfast: The Week Ahead
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22